Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcoma ABOSTO:ARCOMA +1.89%74 EV-to-EBIT is 20.54 as of Aug. 19, 2026, which is 94% above its 10-year median of 10.61. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 74/100 and a GF Value™ of kr7.91 (Fairly Valued). The stock has 5 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Arcoma AB ranks worse than 54.87% on this metric.
The historical rank and industry rank for Arcoma AB's EV-to-EBIT or its related term are showing as below:
OSTO:ARCOMA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -638.3 Med: 10.61 Max: 1759.31
Current: 20.54
During the past 13 years, the highest EV-to-EBIT of Arcoma AB was 1759.31. The lowest was -638.30. And the median was 10.61.
OSTO:ARCOMA's EV-to-EBIT is ranked worse than 54.87% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.185
vs OSTO:ARCOMA: 20.54
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Arcoma AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr80.5 Mil.
Arcoma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB EV-to-EBIT Related Terms
Arcoma AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Arcoma AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARCOMA vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Arcoma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Arcoma AB's EV-to-EBIT falls into.
Arcoma AB's current Enterprise Value is kr99.7 Mil.
Arcoma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB (OSTO:ARCOMA) has a EV-to-EBIT of 20.54 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arcoma AB and its competitors. This is 94% above median its historical median of 10.61. According to the industry distribution chart, Arcoma AB ranks #259 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 54.9%.
Is Arcoma AB's EV-to-EBIT too high?
Arcoma AB's current EV-to-EBIT of 20.54 is 94% above median its 10-year median of 10.61. The Medical Devices & Instruments industry median EV-to-EBIT is 19.19. Arcoma AB's value of 20.54 is 7.1% above this industry median. Based on the distribution chart, Arcoma AB ranks #259 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Arcoma AB has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #259 out of 472 companies for EV-to-EBIT. This places Arcoma AB in the lower half of its industry. The industry median EV-to-EBIT is 19.19. Arcoma AB's value of 20.54 is 7.1% above this benchmark. While the company's 10-year median is 10.61 vs. the industry median of 19.19, Arcoma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.19, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current EV-to-EBIT of 20.54 is 7.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current EV-to-EBIT is 20.54, which is 94% above median its own 10-year median of 10.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.91, compared to a current price of kr8.64 — trading 9.2% above its estimated fair value. The current EV-to-EBIT is 20.54, which is 94% above median its 10-year median of 10.61 and 7.1% above the Medical Devices & Instruments industry median of 19.19. Arcoma AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current EV-to-EBIT is 20.54 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.64 is trading 9.2% above its estimated GF Value™ of kr7.91.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
EV-to-EBIT: 20.54 (94% above median its 10-year median of 10.61)
GF Value™: kr7.91 vs. price of kr8.64 (9.2% above fair value)
Industry Position: 7.1% above the Medical Devices & Instruments median (#259 of 472)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
74GF Score
Get the complete analysis for OSTO:ARCOMA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
